The Non-invasive Serum Biomarkers Contributes to Indicate Liver Fibrosis Staging and Evaluate the Progress of Chronic Hepatitis B

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Jun 26

PMID 38926648

Authors

Shaoxiong Zeng

Zhenzhen Liu

Bilun Ke

Yiwang Zhang

Qian Wang

Siwei Tan

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to evaluate the diagnostic abilities of the non-invasive serum biomarkers to predict liver fibrosis staging and evaluate the progress of hepatitis B.

Methods: We enrolled 433 patients with chronic HBV infection had complete medical data available for the study, who underwent percutaneous liver biopsy. The extent of fibrosis was assessed using the modified METAVIR score. The predictive values of the non-invasive serum biomarkers were evaluated by the areas under the receiving operator characteristics curves (AUROCs) with 95% confidence intervals.

Results: The proportion of males with progressive stages of liver fibrosis was relatively larger, and the average age of patients with cirrhosis stages is older than the non-cirrhotic stages. We found PLT, GGT, ALP, TB, FIB4 and GPR to be significantly associated with liver fibrosis in our cohort. GGT showed a sensitivity of 71.4% and specificity of 76.7% in distinguishing cirrhosis (F4) from non-cirrhotic stages (F1-3), with an AUROC of 0.775 (95%CI 0.711-0.840).The AUROCs of the GPR in distinguishing cirrhosis (F4) from non-cirrhotic stages (F1-3) was 0.794 (95%CI 0.734-0.853), but it had a lower sensitivity of 59.2%. Additionally, GGT, FIB4, and GPR could differentiate advanced fibrosis (F3-4) from non-advanced fibrosis (F1-2) among individuals with chronic hepatitis B, with AUROCs of 0.723 (95%CI 0.668-0.777), 0.729 (95%CI 0.675-0.782), and 0.760 (95%CI: 0.709-0.811) respectively.

Conclusions: GGT was a better biomarker to distinguish cirrhosis (F4) from non-cirrhotic stages (F1-3), while GPR was a better biomarker to identify advanced fibrosis (F3-4) and non-advanced fibrosis (F1-2) in patients with chronic hepatitis B.

Citing Articles

Correlation Between Clinical Indicators and Liver Pathology in Children with Chronic Hepatitis B.

Huang C, Lu Y, Wang Z, Jiang Q, Dong Y, Cao L Biomedicines. 2025; 12(12.

PMID: 39767809 PMC: 11726914. DOI: 10.3390/biomedicines12122903.

References

Lens S, Torres F, Puigvehi M, Marino Z, Londono M, Martinez S . Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2015; 43(3):364-74. DOI: 10.1111/apt.13472. View

Huang R, Wang G, Tian C, Liu Y, Jia B, Wang J . Gamma-glutamyl-transpeptidase to platelet ratio is not superior to APRI,FIB-4 and RPR for diagnosing liver fibrosis in CHB patients in China. Sci Rep. 2017; 7(1):8543. PMC: 5561053. DOI: 10.1038/s41598-017-09234-w. View

Liu D, Lu W, Zhang Z, Wang Y, Ding R, Zhou X . Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B. J Viral Hepat. 2017; 25(5):581-589. DOI: 10.1111/jvh.12842. View

Colloredo G, Guido M, Sonzogni A, Leandro G . Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003; 39(2):239-44. DOI: 10.1016/s0168-8278(03)00191-0. View

Bedossa P, Poynard T . An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2):289-93. DOI: 10.1002/hep.510240201. View

Petta S, Wong V, Camma C, Hiriart J, Wong G, Vergniol J . Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. Aliment Pharmacol Ther. 2017; 46(6):617-627. DOI: 10.1111/apt.14219. View

Shiha G, Ibrahim A, Helmy A, Sarin S, Omata M, Kumar A . Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2016; 11(1):1-30. DOI: 10.1007/s12072-016-9760-3. View

Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T . Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357(9262):1069-75. DOI: 10.1016/S0140-6736(00)04258-6. View

Karkmann K, Piecha F, Runzi A, Schulz L, von Wulffen M, Benten D . [Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures]. Z Gastroenterol. 2018; 56(1):55-69. DOI: 10.1055/s-0043-124000. View

10.

Fujita K, Oura K, Yoneyama H, Shi T, Takuma K, Nakahara M . Albumin-bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C. Hepatol Res. 2019; 49(7):731-742. PMC: 6851801. DOI: 10.1111/hepr.13333. View

11.

Moon A, Singal A, Tapper E . Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2019; 18(12):2650-2666. PMC: 7007353. DOI: 10.1016/j.cgh.2019.07.060. View

12.

Seeff L . Natural history of chronic hepatitis C. Hepatology. 2002; 36(5 Suppl 1):S35-46. DOI: 10.1053/jhep.2002.36806. View

13.

Morikawa H, Fukuda K, Kobayashi S, Fujii H, Iwai S, Enomoto M . Real-time tissue elastography as a tool for the noninvasive assessment of liver stiffness in patients with chronic hepatitis C. J Gastroenterol. 2010; 46(3):350-8. DOI: 10.1007/s00535-010-0301-x. View

14.

Bravo A, Sheth S, Chopra S . Liver biopsy. N Engl J Med. 2001; 344(7):495-500. DOI: 10.1056/NEJM200102153440706. View

15.

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

16.

Li Q, Li W, Huang Y, Chen L . The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBeAg-positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China. J Viral Hepat. 2016; 23(11):912-919. DOI: 10.1111/jvh.12563. View

17.

Li M, Wang Z, Zhang L, Zheng H, Liu D, Zhou M . Burden of Cirrhosis and Other Chronic Liver Diseases Caused by Specific Etiologies in China, 1990-2016: Findings from the Global Burden of Disease Study 2016. Biomed Environ Sci. 2020; 33(1):1-10. DOI: 10.3967/bes2020.001. View

18.

Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V . FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007; 46(1):32-6. DOI: 10.1002/hep.21669. View

19.

Seto W, Lo Y, Pawlotsky J, Yuen M . Chronic hepatitis B virus infection. Lancet. 2018; 392(10161):2313-2324. DOI: 10.1016/S0140-6736(18)31865-8. View

20.

Xu S, Li Q, Hu Y, Ying L . Development of a model based on biochemical, real‑time tissue elastography and ultrasound data for the staging of liver fibrosis and cirrhosis in patients with chronic hepatitis B. Mol Med Rep. 2016; 14(4):3609-19. PMC: 5042746. DOI: 10.3892/mmr.2016.5682. View